Introduction
Airway hemangiomas (AHs) are the most common neoplasm of the infant airway, but they are benign tumors with spontaneous regression during infancy. 1 Infants who have AHs usually have symptoms of respiratory tract obstruction with biphasic stridor before 6 months of age. 1 These symptoms are occasionally diagnosed as recurrent croup. Clinicians often evaluate the airway of infants with obstructive symptoms and cutaneous infantile hemangiomas (CIHs), especially those in a beard-like distribution, because of concern that AH might also be present. 2 The natural history of infantile hemangiomas is characterized by a proliferative phase followed by an involution phase. 3 Despite their self-limited course, AHs can cause respiratory compromise during infancy secondary to airway obstruction. 1 Approaches used in managing AH include tracheostomy, short-term intubation, 4 CO 2 or other types of laser surgery, 5 submucosal resection via an open surgical approach, intralesional steroid injection, 6 systemic steroids, interferon, 7 and vincristine, 8 as well as observation. The various treatments have been used alone or in combination, but they are associated with limitations and complications.
Since 2008, propranolol has been used as primary treatment for AH at Riley Hospital for Children at Indiana University Health, based on CIH data reported by Léauté-Labrèze et al. 9 They found that propranolol treatment resulted in regression or stabilization of CIHs without side effects. Based on these promising results, many centers have begun using propranolol as primary treatment for patients with CIH. 10 Since the 2009 American Society of Pediatric Otolaryngology meeting, two published studies have reported promising results for the use of propranolol in treating AH in infants. 11, 12 To date, the largest published report only included 2 patients.
We are reporting the clinical outcomes for 5 infants who were treated with propranolol for glottic and subglottic hemangiomas. Our aim was to add to the ENT-Ear, Nose & Throat Journal  April/May 2013 body of evidence in support of propranolol as first-line treatment for AH.
Patients and methods
We retrospectively reviewed the medical records of 5 consecutive infants under 2 years of age who received propranolol treatment for AH between August 2008 and July 2010; 4 of these patients had subglottic hemangiomas, and 1 had a glottic hemangioma. All patients had documented AH on flexible bronchoscopy or flexible laryngoscopy. All patients were treated with oral propranolol (2 mg/kg/day in divided doses administered 3 times daily); they were not concurrently receiving any other treatment. Key clinical features of the 5 cases are summarized in the table.
At the time of propranolol initiation, parents of all patients were fully informed of (1) the potential but unconfirmed role of propranolol, (2) propranolol's possible side effects (hemodynamic compromise, bronchospasm, hypoglycemia, etc.), (3) and other therapeutic options for AH. All patients were admitted to the hospital during initiation of propranolol therapy. They were placed on continuous cardiopulmonary monitoring and were watched for clinical signs of hypoglycemia. Between August 2008 and July 2010, no other patients received a different treatment for AH. The review of medical records was approved by the Institutional Review Board at Indiana University.
Based on our experience and the recommendations of others, we have developed a proposed treatment algorithm (figure).
Results

Patient 1.
A 2-month-old boy was admitted for worsening barking cough of 3 weeks' duration associated with chest retractions and increased effort in breathing. The patient previously had been treated with inhaled albuterol and systemic methylprednisolone without clinical improvement.
Biphasic, moderately high-pitched upper airway stridor and chest retractions were noted on the patient's physical examination. Flexible bronchoscopy performed by one of our pulmonary investigators revealed a subglottic hemangioma. Oral propranolol, 2 mg/kg/day in divided doses administered 3 times daily, was started. The patient was observed continuously with pulse oximetry and cardiac monitoring. Marked clinical improvement with regression of stridor was noted, and the patient was hemodynamically stable without any desaturations or an objective increase in respiratory rate during propranolol treatment.
The patient was discharged the day after initiation of propranolol. He was regularly evaluated as an outpatient for the subsequent 10 months. Follow-up flexible bronchoscopy after 3 months of propranolol treatment still showed subglottic hemangioma, but the airway obstruction it had caused was diminished. Furthermore, the patient had symptomatically improved. Propranolol was increased based on the patient's weight throughout the treatment period (6 months).
During propranolol treatment, the patient had occasional flushing of the face and hands without other cardiovascular or respiratory concerns. However, he received short-term treatment with systemic corticosteroids of an unknown duration once for mild croup symptoms at 5 months of age. He was weaned off propranolol over the course of a week after 6 months of treatment because he had symptomatically improved.
Two weeks after discontinuation of propranolol, the patient was admitted for worsening stridor and chest retractions because his symptoms did not improve with oral prednisone. He was treated with intravenous dexamethasone, resulting in clinical improvement, and was able to be discharged the next day. No airway exami- nation was performed at that time. Three months after being successful weaned from the 6-month course of propranolol treatment, the patient had only mild inspiratory stridor on rare occasions. Patient 2. A 2-month-old boy was admitted for inspiratory stridor. He was initially treated with racemic epinephrine and intravenous dexamethasone, which improved the symptoms slightly. On physical examination, a facial CIH from the left side of the lip to the right preauricular area (beard-like distribution) and a CIH in the occipital area were noted. Flexible laryngoscopy revealed an erythematous discoloration along the lateral aspect of the right true vocal fold, consistent with glottic hemangioma.
The patient was treated with the aforementioned propranolol protocol without any hemodynamic compromise during a subsequent 24-hour period of observation. There were neither desaturations nor an objective increase in respiratory rate throughout the hospital course. Stridor improved, and the patient was discharged the following day. No further follow-up could be obtained because the patient was a resident of Florida and the respiratory event occurred during a trip to Indiana. Patient 3. A 2-month-old boy was transferred from an outside hospital for noisy breathing. Prior to transfer he had received inhaled levalbuterol, oral prednisolone, and amoxicillin for presumed croup at the outside hospital without relief. On physical examination, biphasic stridor and chest retractions were noted. Flexible bronchoscopy demonstrated a narrowing in the subglottis due to an erythematous mass at the 7 o' clock position, consistent with subglottic hemangioma.
The patient was placed on propranolol at 2mg/kg/day, and a marked resolution of the symptoms was noted within 12 hours. The patient remained hemodynamically stable and experienced no oxygen desaturations or an objective increase in respiratory rate throughout the hospital course. He was discharged the next day and was followed periodically for the next 11 months. The propranolol dosage was increased at each follow-up visit because of interval weight gain. No adverse event related to propranolol was reported by the parents.
The patient had one Emergency Department (ED) visit at 8 months of age for worsening barking cough and was treated with a 5-day course of oral prednisone. No airway examination was performed at that time. Otherwise, no other systemic corticosteroids were needed during propranolol treatment. Follow-up flexible bronchoscopy After discontinuation of propranolol, the patient had 2 more ED visits due to croupy cough and chest retractions. Both illnesses were treated with oral prednisone, resulting in clinical improvement in the stridor. Again, no airway examination was performed at that time.
During follow-up visits after discontinuation of propranolol, mild inspiratory stridor, mild chest wall retractions, and occasional biphasic, mild wheezy sounds from the larynx were noted on physical examination. Although the patient had no signs of asthma or bronchospasm, because of his previous clinical response to systemic corticosteroid treatment and because of the somewhat worsening findings, inhaled budesonide was started. Since then, the patient has not had any other acute respiratory events requiring systemic corticosteroid treatment. Inhaled budesonide was discontinued 3 months after it was initiated. No worsening of stridor or other respiratory symptoms was noted without the inhaled budesonide.
Patient 4. A 2-month-old girl was admitted for evaluation of stridor. Her medical history included treatment with 1 dose of oral corticosteroids for croup 1 month earlier. Flexible bronchoscopy revealed a subglottic mass located at the posterior midline, obstructing the airway 50 to 75%. The appearance of the subglottic mass was consistent with subglottic hemangioma. On physical examination, biphasic stridor without chest retractions was noted. Two CIHs were also noted on at the left shoulder and the right side of the abdomen. Propranolol was started.
During hospitalization, the patient remained hemodynamically stable and was discharged home the following day because the stridor had regressed. No desaturations or objective increases in respiratory rate were observed throughout the hospital course.
The patient was followed for 5 months after initiation of propranolol. Throughout the follow-up period, inspiratory stridor was only noted during an upper respiratory infection, without associated respiratory distress. The CIHs were also improved. The propranolol dosage was increased as necessary for interval weight gain. The patient did not require any systemic corticosteroids. Follow-up flexible bronchoscopy at 7 months of age revealed a marked decrease in the size of the subglottic hemangioma.
Patient 5.
A 2-month-old girl was admitted for worsening biphasic stridor. Her medical history was significant for a 3 × 3.5-cm right posterolateral CIH near the occiput, but she was otherwise healthy. Stridor had begun initially at 1 month of age and had worsened gradually over the next 3 weeks. She had been seen previously in the ED, 1 month prior to admission, for similar, yet milder, symptoms without improvement on nebulized albuterol treatments. The presumed diagnosis at that time was upper respiratory infection. She was seen shortly thereafter by her primary care physician and was placed on a short-term course of oral corticosteroids without improvement in her symptoms.
The patient had been scheduled for an outpatient flexible bronchoscopy, but her parents decided to bring her back to the ED for fear that she would stop breathing. She was initially admitted to the pediatric ward, but 1 hour after admission, she required transfer to the intensive care unit (ICU) for increasing stridor and oxygen desaturation to the 70 to 80% range. She was noted to have significant subcostal retractions for which she was given vaporized racemic epinephrine and dexamethasone intravenously once. She was additionally placed on supplemental oxygen.
Flexible bronchoscopy revealed a submucosal sublgottic mass, smooth and mildly dark blue, posteriorly and on the right, consistent with hemangioma. The patient was started on propranolol at 0.5 mg/kg/day in divided doses 3 times daily; the dosage was slowly increased over the next 48 hours to 2 mg/kg/day in divided doses administered 3 times daily, 13 and corticosteroids were discontinued.
The patient remained hemodynamically stable and was without any clinical signs of hypoglycemia. Within 24 hours she was clinically improving, with resolution of the stridor and the need for supplemental oxygen. Her CIH was also noted to be reduced in size and color. Three weeks later, she was brought back to the ED because she was spitting up dark-brown mucus. As she was doing well upon presentation, no further treatment was given at that time. She has not been seen again as an outpatient.
Discussion
Propranolol is a nonselective beta-blocker. The mechanism for its therapeutic effect has not been fully understood. One possible explanation is vasoconstriction. This effect is immediately visible with a color change to the CIH. Other explanations are a decreased expression of vascular endothelial growth factor and basic fibroblast growth factor, 14 and apoptosis of capillary endothelial cells. 15 One has to compare the risk-benefit ratio of other treatment modalities to several months of treatment with propranolol. Potential side effects of propranolol include bradycardia, hypotension, bronchoconstriction, and hypoglycemia, yet these side effects are usually seen in newborns in the first weeks of life and less seen in otherwise healthy infants. 16 Denoyelle et al propose that this therapy should not be used without a full cardiovascular review, including baseline cardiac ultrasonography, electrocardiography, and cardiologic examination. 17 As our patients did not have very large hemangiomas, further cardiac workup was not initiated as proposed by Siegfried et al, who recommend glucose monitoring during the first 48 hours. 13 This was not done because all of our patients were able to resume their normal diets.
In our case series we observed an immediate clinical improvement in symptoms of upper airway obstruction upon initiation of propranolol therapy, although the visible change in the hemangioma was not obvious as is seen with CIHs. We do not have a clear explanation for the discrepancy in therapeutic response to propranolol between AH and CIH, although a recent study showed that most subglottic hemangiomas have histopathologic and immunophenotypic profiles similar to those of infantile hemangiomas in other anatomic locations. 18 Glucose transporter 1 (GLUT-1) has been a useful immunohistochemical marker that distinguishes hemangiomas from vascular malformations. Since we did not biopsy any of our patients' lesions, they might not have been positive for GLUT-1 and therefore actually might not have been hemangiomas. 19 This may explain why not all lesions responded similarly. However, the clinical pictures were strongly consistent with AH, and the likelihood of a different diagnosis to explain the findings was remote.
The clinical improvement with propranolol treatment was most impressively noted soon after initiating the drug. Marked improvements in inspiratory stridor, chest retraction, and other signs of upper airway obstruction were observed by parents and the medical care team less than 24 hours after treatment initiation, without side effects.
All patients in our case series tolerated propranolol well, without hypotension, arrhythmia, or other cardiovascular adverse events. Beta-blocker-associated respiratory complications also were not observed in our patients. Only one side effect (cutaneous flushing) was reported in 1 patient during the follow-up period. As propranolol is known to cause vasoconstriction, this was an unusual side effect. Because we are reporting on a small, retrospective case series and the period of follow-up is not very long (i.e., less than 1 year), the long-term effects of propranolol used in young infants is not known at this time, and we concede that some patients may require more aggressive treatment than propranolol.
Another limitation of our study is the lack of formal rigid bronchoscopy, which would allow for higherresolution pictures. Because of referral patterns at our institution, most patients initially presented to the pulmonary service for flexible bronchoscopy. We did not feel it was necessary to put patients under general anesthesia just for documentation purposes, as they had been adequately diagnosed with AH by the pulmonary service and had improved on propranolol, supporting the diagnosis of AH.
All of our patients had a clinical improvement in their respiratory symptoms over time while on propranolol. In the patients who had continued upper airway noise, gastroesophageal reflux disease (GERD) might have had some contribution, as 3 of our patients also had diagnoses of laryngopharyngeal or gastroesophageal reflux prior to initiation of propranolol. One can assume that propranolol might have worsened GERD, as this is a known side effect of the drug.
The impact of propranolol on our patients' clinical improvement cannot be measured at this time, and it could have simply resulted from the natural course of the disease. However, our patients did not require longterm daily oral corticosteroids or surgical intervention.
The optimal treatment duration with propranolol has yet to be determined. Maturo and Hartnick believe that it should be continued until at least the first year of life, as this is when the proliferative phase of AH is completed. 16 In conclusion, in our case series we found a clinical response of AH to propranolol treatment without major side effects. Our findings provide additional evidence that propranolol can be an effective and safe initial treatment for symptomatic subglottic and glottic hemangiomas.
